Resultados de búsqueda - Michael Tees

  • Mostrando 1 - 5 Resultados de 5
Limitar resultados
  1. 1
    Non-soy legume consumption lowers cholesterol levels: A meta-analysis of randomized controlled trials

    Non-soy legume consumption lowers cholesterol levels: A meta-analysis of randomized controlled trials por Lydia Bazzano, Angela M. Thompson, Michael Tees, Catherine Nguyen, Donna M. Winham

    Publicado 2009
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  2. 2
    Hurricane Katrina-Related Maternal Stress, Maternal Mental Health, and Early Infant Temperament

    Hurricane Katrina-Related Maternal Stress, Maternal Mental Health, and Early Infant Temperament por Michael Tees, Emily W. Harville, Xu Xiong, Pierre Buekens, Gabriella Pridjian, Karen Elkind‐Hirsch

    Publicado 2009
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  3. 3
    Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

    Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expa... por Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle M. Brander, Michael Tees, Sameer A. Parikh, Tycel Phillips, Razi Ghori, Nishitha Reddy, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens

    Publicado 2022
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  4. 4
    A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

    A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/... por Alexey V. Danilov, Michael Tees, Krish Patel, William G. Wierda, Manish R. Patel, Ian W. Flinn, Tahir Latif, Weiyun Z. Ai, Meghan C. Thompson, Michael Wang, Clare Sun, Deborah M. Stephens, Michael J. Thirman, Melissa Gessner, Johannes Wolff, Amanda Schwab, May Tan, Daniel C. Chan, Erin Meredith, Adrian Wiestner

    Publicado 2023
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

    NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cel... por Anthony R. Mato, William G. Wierda, Weiyun Z. Ai, Ian W. Flinn, Michael Tees, Manish R. Patel, Krish Patel, Susan O’Brien, David A. Bond, Lindsey E. Roeker, Tanya Siddiqi, Michael Wang, Clare Sun, Omar Abdel‐Wahab, Amanda Schwab, May Tan, Erin Meredith, Melissa Gessner, Su Young Kim, Adrian Wiestner, Alexey V. Danilov

    Publicado 2022
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: